Are Veterinary Consolidators Still Buying in 2026? What the Data Shows

July 15, 2026

Veterinarian reviewing an acquisition offer for their practice

Are Veterinary Consolidators Still Buying in 2026? What the Data Shows

Key takeaways

Yes, consolidators are still buying — Capstone Partners’ April 2026 Pet Sector M&A Update recorded 18 announced or completed transactions in the pet sector year-to-date, more than double the prior-year pace, with 9 in the vet and health segment alone.
The largest platforms have shifted focus to operations, but mid-tier buyers are the most aggressive acquirers. Groups with fresher PE capital and room on their balance sheets are competing actively for quality practices in 2026.
Multi-doctor practices are still the prime target. Consolidators have raised their minimum criteria — most actively pursue practices with $2M or more in annual revenue, and the strongest multiples go to multi-doctor clinics with low owner-dependency.
The VSO vs. VPO split matters more than it used to. Per Octus’s 2025 private-credit analysis, VPO-model platforms (where doctors retain equity) have significantly outperformed full-acquisition VSO platforms in fair value — a signal about which model has proved more durable under pressure.
A single direct offer is still almost never the best you can do. The gap between a one-buyer negotiation and a structured competitive process consistently runs into the hundreds of thousands or millions on any meaningful practice.

An owner called me over dinner last fall with a question I’ve been hearing more often as the market has matured. She’d been running a 3-doctor general practice for almost 20 years, revenue close to $3 million, strong reputation in her town.

She had an offer sitting in front of her from a PE-backed group’s acquisition team. The number wasn’t bad.

But she’d been reading things. Articles about consolidators pulling back.

The occasional headline about a big group struggling with debt. And so her question was simple: “Is the buying actually still happening, or am I catching the end of something?”

It’s the right question, and I want to answer it with actual data rather than reassurance.

Are veterinary consolidators still buying in 2026? The direct answer: yes, and deal volume in the vet sector has accelerated materially from where it sat a year ago. What’s changed is who is buying most aggressively and what they’re looking for.

Understanding that distinction is worth more to a seller than any general “yes the market is fine” headline.

What the 2026 deal data shows

Capstone Partners‘ April 2026 Pet Sector M&A Update reported 18 announced or completed transactions in the pet sector year-to-date — more than double the 8 recorded in the same period a year earlier. The vet and health segment accounted for 9 of those 18 deals.

That’s not a market in retreat.

Strategic buyer activity climbed to 10 transactions year-to-date in 2026 compared to just 3 in the equivalent 2025 window, per Capstone. Capstone’s analysts attributed the acceleration partly to carry-over from deals that were negotiated in 2025 but didn’t close before year-end, plus a healthy rebound in buyer appetite entering 2026.

That context matters. Deal velocity in individual practice acquisitions did compress from 2022 to 2024, when rising interest rates made debt-financed platform recapitalizations more expensive and slowed the mega-consolidator activity.

But the rate pressure on large-platform-to-platform deals doesn’t translate cleanly to the practice level, where PE-backed groups are still deploying equity out of existing credit facilities. Individual practice M&A and platform-level M&A run on different dynamics, and sellers need to understand which clock they’re actually on.

The practice-level acquisition market has been consistent. There’s no interval in the past 4 years when serious multi-doctor practices in good markets were unable to attract interest from qualified buyers.

What fluctuates is the number of buyers competing and how aggressively they bid — and 2026 is opening with more deal velocity than 2025 did.

Are veterinary consolidators still buying in 2026? A sector-by-sector look

The consolidator landscape in 2026 isn’t monolithic. Different groups are in very different phases, and that shapes their acquisition appetite.

The mega-platforms: focused on operations, not land-grabs

The largest PE-backed platforms, the ones that ran the most aggressive expansion phases from 2018 to 2022, are spending 2025 and 2026 doing something different. Today’s Veterinary Business called it the Great Compression, now in its third year: the spotlight has shifted from who’s buying to who’s holding on and improving margins.

That’s not a retreat from acquiring. It’s a maturation.

Groups like VetCor, backed by Harvest Partners and Cressey & Company with over 900 hospitals in its network, continue to pursue individual practice acquisitions. Mission Pet Health, the combined entity formed when Southern Veterinary Partners and Mission Veterinary Partners merged in late 2024 and launched their unified brand in July 2025, operates over 750 animal hospitals under Shore Capital’s sponsorship and is one of the most actively watched acquisition platforms in the market. These groups have the scale to absorb high-quality practices; what they’re not doing is paying premium prices for average performers.

The dynamics behind that are straightforward. Elevated debt costs from 2022 forward made platform recapitalizations — the process where a PE sponsor sells a large consolidator to another PE sponsor at a higher multiple — harder to execute at the valuations earlier vintages expected.

Not all groups passed the stress test. Thrive Pet Healthcare, with more than 360 locations, completed a capital extension in early 2025 to stabilize its balance sheet and give itself room to strengthen operations rather than chase new acquisitions.

This tiering effect is real: well-capitalized groups with strong operational metrics are buying aggressively; overleveraged groups that expanded too fast are not. The seller who understands that distinction and targets the right buyer pool is the one who captures competitive bids in 2026.

Mid-tier and emerging consolidators: the most aggressive acquirers

The buyers who made the most news in late 2025 and early 2026 weren’t the largest platforms. They were the mid-tier and emerging PE-backed groups with fresher capital and explicit acquisition mandates.

AmeriVet Veterinary Partners, backed by AEA Investors and Oaktree Capital, acquired Northeast Veterinary Partners in November 2025 — the first time AmeriVet purchased another consolidator rather than individual practices, bringing its network to over 186 clinics. AmeriVet has since received a minority investment from OPTrust, one of Canada’s largest pension funds, which deepens its acquisition capacity.

United Veterinary Care, backed by TA Associates, continues its US expansion. Heartland Veterinary Partners, backed by Gryphon Investors, remains active in the Midwest. Companion Pet Partners, backed by Cortec Group, has been consistent in its southeast and mid-Atlantic acquisition focus. Across the consolidator landscape, the mid-tier groups with PE sponsors in years 3 to 7 of a typical fund cycle have both the capital and the urgency to add high-quality hospitals to their platforms.

Mars Veterinary Health remains the major strategic exception to the PE-backed model. Mars, family-owned by Mars Inc. and operating through VCA, Banfield, and BluePearl, approaches acquisitions with a different time horizon and different financial constraints than PE-backed buyers.

Mars conversations tend to be longer and structurally different; the process is worth understanding before entering it.

For a full look at the consolidator landscape and which groups operate in which geographies, the veterinary practice consolidators guide goes deep on each major buyer.

The VSO vs. VPO split: what the private-credit data reveals

One of the most useful signals on consolidator health in 2026 comes from an unexpected source: private-credit fair value data.

Octus, which tracks private-credit exposure to veterinary rollups across business development companies, identified 15 veterinary companies operating across 5 distinct business models, with BDCs holding $3.1 billion in principal lent to those companies as of Q3 2025. The fair-value dispersion within that pool tells the real story of which consolidator models are holding up.

Veterinary service organizations (VSOs) — consolidators that acquire practices outright and convert veterinarians to salaried employees — showed an average fair value of 97.4% of par but ranged from 88% to 101.2%, per Octus’s September 2025 analysis. That wide spread reflects something structural: when a vet becomes a salaried employee with no economic stake in the platform’s success, the alignment and retention dynamics that made the practice valuable in the first place can erode.

Veterinary partnership organizations (VPOs) — consolidators that take a majority stake of typically 60 to 80 percent while the selling doctor retains 20 to 40 percent as a continuing partner — performed meaningfully better, with an average fair value at par. The VPO model creates ongoing economic alignment between the doctor and the platform, which drives better retention and, per Octus’s analysis, more durable operational performance.

What does this mean for a seller? The structure of the offer matters as much as the headline number. A VPO offer where you retain meaningful equity in a well-capitalized platform may outperform a full VSO acquisition at a slightly higher multiple, particularly if the platform’s PE sponsor has a clear exit runway and the equity you retain converts into a second check. We explain earnout and rollover equity mechanics in their own piece.

The point here is that the private-credit data validates what sellers who’ve lived through it already know: not all consolidator structures are equal, and the smart money in 2026 is distinguishing between them.

Consolidator model	What it means for the seller	Octus 2025 private-credit signal
VSO (full acquisition, salaried doctor)	Seller exits entirely; clean break; no ongoing equity stake	Average 97.4% of par; wide dispersion (88%–101.2%)
VPO (majority stake, doctor retains equity)	Seller takes partial cash at close, retains 20–40% for a second close	Average at par; tighter clustering; stronger retention data
Hybrid (mixed approaches)	Varies by group; case-by-case deal structure	Near par; some weakness in subordinated positions

What consolidators are actually looking for in 2026

The question “are they still buying?” is incomplete without asking “what are they buying?” The acquisition criteria have sharpened since the land-grab years.

Multi-doctor practices are the primary target. Consolidators believe the most resilient market going forward is for 4-plus doctor practices, where production is distributed, the practice is not dependent on a single owner-DVM, and an associate bench exists for post-close continuity. A solo practice isn’t un-sellable, but it typically attracts offers from smaller regional groups rather than the largest platforms, and the multiple reflects the additional transition risk.

Revenue thresholds have risen. Most PE-backed groups have tightened their minimum acquisition criteria. The largest consolidators routinely focus on practices generating $3 million or more in annual revenue.

Mid-tier groups go down to $1.5 million to $2 million but don’t advertise a floor below that. A practice doing $800,000 in revenue is interesting to a local multi-site operator; it rarely enters the institutional buyer pool.

Operational systems matter more than they did. The efficiency-focused phase of consolidation has made buyers scrutinize scalability before they bid. A practice where scheduling, records, and clinical workflows run on documented systems is a faster integration than one running on tribal memory.

Buyers underwrite integration cost; documented systems lower that cost and often lift the multiple.

Financial documentation is non-negotiable. Buyers are running deeper diligence than they did during the growth sprint. A practice with 3 years of clean P&Ls, a defensible normalized EBITDA (what the practice earns in pure operating profit, before taxes and accounting choices), and a clear story for how the revenue survives ownership transition moves through buyer review faster and with fewer retrades.

For the full picture of how who to sell your veterinary practice to depends on your practice’s size, structure, and geography, that’s worth reading before you engage any buyer.

The regulatory layer: what antitrust scrutiny means for sellers

One dynamic that’s changed the consolidation landscape in 2026 is heightened regulatory attention. Holland & Knight’s year-end 2025 healthcare antitrust report identified a continuing bipartisan focus on healthcare consolidation at the state level.

The FTC has been actively monitoring veterinary M&A and has required divestiture from at least one firm that had accumulated a large enough local concentration of practices, per Paul Hastings LLP’s analysis of FTC activity in the space. New York has introduced legislation requiring advance notice for veterinary clinic acquisitions above certain thresholds, with filings to go to the state Department of Agriculture and Markets.

None of this has stopped the market. But it has changed the shape of deals at the platform-recapitalization level — the mega-consolidator-to-mega-consolidator transactions that involve thousands of hospitals face more scrutiny than they did in 2019.

Individual practice acquisitions, where a single-location or small-group practice joins an existing platform, are well below the Hart-Scott-Rodino Act thresholds that trigger mandatory FTC review.

For a seller, the practical implication is simple: the antitrust spotlight is on corporate-to-corporate deals, not on a vet selling their practice to a PE-backed group. It doesn’t change the calculus for the typical owner in our world — but it does explain some of the strategic behavior you see from the largest platforms, who are now more deliberate about geographic concentration before they bid on a new hospital.

The real question: direct offer vs. competitive process in 2026

A veterinarian and a sell-side advisor review printed practice valuation terms together at a table, looking down at the documents, natural light, unposed

The owner I mentioned at dinner had one more question after she heard the market is still active. It came out the way it always does: “So should I just take this offer?”

The offer in front of her was from one buyer in one conversation. That’s the structure of a direct offer: one party sets the terms with knowledge that no other bid is coming.

It’s calibrated accordingly.

What changes everything is bringing that same practice to 4, 6, 8 qualified buyers simultaneously, with a structured bidding window and a clear process. The buyers who want the practice have to compete, and that competition is what moves the number from where the buyer wanted to start to where the seller deserves to land.

I’ve seen this dynamic enough times that I’ve stopped calling it a surprise. Across the deals we’ve closed over the past four-plus years, the gap between a single direct offer and the result of a real competitive process runs consistently large.

It’s almost never less than several hundred thousand dollars on a meaningful practice. Often it’s more.

Nearly all of that gap lands in a higher multiple, which compounds against the same EBITDA base.

Per industry M&A commentary from Capstone Partners and Octus across 2025-2026, the typical PE-backed offer structure allocates the majority of total deal value to cash at close, with the remainder across earnout, rollover equity, and occasionally a seller note. The multiple — the multiplier buyers apply to your EBITDA to set the price — is the lever that the competitive process moves. And moving it even one or two turns on a practice generating $600,000 in EBITDA means $600,000 to $1.2 million in additional sale value.

That’s the math on the gap. It’s not theoretical.

It shows up in our work.

The methodology we use is the Elite Selling System: we hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people, then open a private competitive window inside that vetted group. The leverage that creates is what drives the multiple up.

And in a market where consolidators are active, well-capitalized, and still buying — as 2026 clearly is — that competitive tension is real, not manufactured.

For a deeper look at how private equity values and prices vet practices, and at how to value your practice before any buyer conversation, those two resources are where I’d send you next.

What to do next

If you’ve been watching the headlines about consolidators and wondering whether now is the right time — the data says the window is open. Deal volume is up.

Buyer appetite is back. The groups with the capital to pay strong multiples for the right practices are actively looking.

The owner’s job is to make sure the practice is positioned for a competitive process rather than a one-buyer negotiation. That starts with knowing what the practice is actually worth, what your normalized EBITDA looks like after the right add-backs, and which buyers are likely to bid most aggressively given your geography, size, and structure.

Get a Free Practice Value Estimate →

We pull your numbers ourselves, build a defensible normalized EBITDA, and show you where your practice falls in the 2026 buyer market, including which groups are likely to compete for it and what a competitive outcome realistically looks like versus the direct offer sitting on your desk. The estimate is free and there’s no obligation.

The Transitions Elite engagement model is success-based — no upfront fees, no retainer — so we only get paid when a deal closes and only out of the value our process actually delivers.

Frequently asked questions

Are veterinary consolidators still buying practices in 2026?

Yes. Capstone Partners‘ April 2026 Pet Sector M&A Update tallied 18 announced or completed transactions in the pet sector year-to-date 2026, more than double the 8 recorded in the same period a year earlier.

The vet and health segment alone accounted for 9 of those 18 deals. The largest PE-backed platforms are focused on operational improvement rather than rapid expansion, but mid-tier and emerging consolidators remain active acquirers, and multi-doctor practices in the $2M-plus revenue range continue to attract competitive interest.

Which veterinary consolidators are most active in 2026?

Mission Pet Health, the combined entity of Southern Veterinary Partners and Mission Veterinary Partners, launched its unified brand in July 2025 with over 750 hospitals and Shore Capital as its PE sponsor, and is among the most active acquirers. AmeriVet Veterinary Partners acquired Northeast Veterinary Partners in November 2025, adding 14 hospitals in its first-ever consolidator-to-consolidator acquisition.

VetCor, backed by Harvest Partners and Cressey and Company, operates over 900 hospitals and continues to pursue individual practice acquisitions. Mid-tier groups with fresher PE capital and room on their balance sheets tend to be the most aggressive buyers in 2026.

Has the pace of veterinary consolidation slowed down?

At the large-platform level, yes — but new deal flow at the practice level has rebounded. The largest PE-backed groups are spending 2025 and 2026 focused on operational efficiency and balance-sheet health rather than rapid new acquisitions.

However, deal volume in the vet and health sector reached 9 transactions in year-to-date 2026 per Capstone Partners, well above the prior-year pace. Smaller and mid-tier consolidators with fresh capital are the most active buyers, and independent practice acquisitions continue at a meaningful rate.

What size practices are consolidators targeting in 2026?

Most PE-backed groups have raised their minimum acquisition criteria. Consolidators generally pursue practices with at least $1 to $2 million in annual revenue, though larger groups increasingly focus on $3 million and above.

Multi-doctor practices command the strongest interest and the highest multiples, because they demonstrate reduced owner-dependency, scalable operations, and the associate bench a buyer needs to sustain production post-closing. Solo practices can still attract offers but typically from smaller regional groups rather than the largest platforms.

What is Mission Pet Health and is it still acquiring vet practices?

Mission Pet Health is the combined entity formed by the merger of Southern Veterinary Partners and Mission Veterinary Partners. The merger formally closed in late 2024, and the unified brand launched July 21, 2025.

Mission Pet Health is backed by Shore Capital Partners and, per its own press materials, operates over 750 animal hospitals across the US. It is one of the most closely watched consolidation platforms in the market and continues to pursue acquisitions of top-performing practices.

How are private equity interest rates affecting vet practice acquisitions in 2026?

Elevated interest rates from 2022 to 2024 made debt-financed acquisitions more expensive and compressed deal volume at the platform recapitalization level. But at the individual practice level, PE-backed groups still fund acquisitions through existing credit facilities and fresh equity from their PE sponsors, so rising debt costs have had less direct effect on practice-level deal prices than on the mega-platform M&A between consolidators.

Dechert’s 2026 PE outlook signals a gradual thaw in sponsor-led activity as rates stabilize.

Is it a good time to sell a veterinary practice to a consolidator in 2026?

For well-run multi-doctor practices, yes. Active buyers, competitive multiples, and a deal market that has rebounded from its 2022 to 2024 trough all favor sellers in 2026.

The owners who capture the strongest outcomes are the ones who run a structured competitive process with multiple qualified bidders rather than accepting a single direct offer. A practice with documented EBITDA of $500,000 or more that generates multiple competing bids consistently clears meaningfully more than the same practice sold in a single-buyer negotiation.

What is the difference between a VSO and VPO model in veterinary consolidation?

A veterinary service organization (VSO) acquires practices outright and converts veterinarians to salaried employees. A veterinary partnership organization (VPO) takes a majority stake — often 60 to 80 percent — while the selling doctor retains 20 to 40 percent equity as a continuing partner.

Per Octus’s 2025 analysis, VPO-model platforms have performed meaningfully better in private-credit fair values than VSO-model platforms, consistent with the thesis that doctor equity participation drives better retention and operational outcomes.